A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Inclusion Criteria:

• Participants must be at least 12 years of age inclusive, at the time the informedconsent is signed.

• Must have participated, received study treatment without permanent investigationalmedicinal product (IMP) discontinuation, and adequately completed the assessmentsrequired for the treatment period in one of the three 24-week parent studiesEFC17559 (COAST-1), EFC17560 (COAST-2) or EFC17561 (SHORE) for moderate-to-severeAD.

• Able and willing to comply with requested study visit and procedures.

• Body weight must be ≥ 25 kg.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Developed a medical condition that would preclude participation as described inPermanent Discontinuation of EFC17559 (COAST-1)/EFC17560 (COAST-2)/EFC17561 (SHORE)clinical trial protocols.

• Having received any prohibited medication or procedure for AD that resulted in IMPdiscontinuation in the parent study EFC17559 (COAST-1), EFC17560 (COAST-2) orEFC17561 (SHORE).

• Participants who, during their participation in the parent study EFC17559 (COAST-1) /EFC17560 (COAST-2)/EFC17561 (SHORE), developed an adverse event (AE) or a seriousadverse event (SAE) deemed related to amlitelimab, which in the opinion of theInvestigator could indicate that continued treatment with amlitelimab may present anunreasonable risk for the participant.

• Participants who have had IMP permanently discontinued for any reason before or atthe time of the planned first dose in the EFC17600 (ESTUARY) study.

• Conditions in the parent study EFC17559 (COAST-1)/EFC17560 (COAST-2)/EFC17561 (SHORE) that led to Investigator - or Sponsor-initiated withdrawal of participantfrom the study (eg, non-compliance, inability to complete study assessments, etc.).

• Participant not suitable for participation, whatever the reason, as judged by theInvestigator, including medical or clinical conditions, or participants potentiallyat risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.